Ali Moosvi, MD
Cardiovascular Disease · Brick, NJNPI 1093796948
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,930 of the $8,821 with a category attached, or 78.6%. It is spread thinly across 52 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,928 and has fallen 58.7% since, to $1,211 in 2025.
Across 444 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2K
- Novartis$688
- Amgen$594
- Abbott$530
- Pfizer$493
- Johnson & Johnson$427
- plus $4K from 46 others
Across 28 payments — averaging $2960.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$83K
What the payments were for
- Travel & lodging$1,65019%
- Food & beverage$6,93079%
- Education$2413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,821 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 477 | $550,376 |
| XareltoRivaroxaban | 234 | $275,731 |
| EntrestoSacubitril/Valsartan | 66 | $87,797 |
| JardianceEmpagliflozin | 50 | $49,942 |
| BrilintaTicagrelor | 51 | $49,891 |
| FarxigaDapagliflozin Propanediol | 37 | $38,770 |
| MultaqDronedarone Hcl | 26 | $37,924 |
| Repatha SureclickEvolocumab | 24 | $31,995 |
| Metoprolol Succinate | 932 | $14,347 |
| Rosuvastatin Calcium | 680 | $10,911 |
| Valsartan | 272 | $8,466 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 152 | $8,217 |
| Atorvastatin Calcium | 593 | $6,782 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 27 | $6,560 |
| Carvedilol ErCarvedilol Phosphate | 14 | $6,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $493 | $550,376477 claims |
| Johnson & JohnsonXarelto | $427 | $275,731234 claims |
| AstraZenecaBrilinta, Farxiga | $342 | $88,66188 claims |
| NovartisEntresto | $688 | $87,79766 claims |
| Boehringer IngelheimJardiance | $270 | $49,94250 claims |
| Sanofi-aventis U.S. LLCMultaq | $72 | $37,92426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Brick
- Aditya MehraBrick$42K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.